Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CAR-T
CAR-T
Celgene, bluebird revise deal to co-develop CAR-T therapy
Biopharma Dive
Thu, 03/29/18 - 11:33 am
Celgene
Bluebird Bio
drug development
CAR-T
bb2121
Multiple Myeloma
Treatment Debates Won’t Slow Down Biotechs
Barron's
Fri, 02/23/18 - 09:50 am
biotech
Gilead Sciences
CAR-T
Juno Therapeutics
Bellicum
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost
Xconomy
Fri, 02/23/18 - 07:59 am
cell therapy
Gilead Sciences
Sangama
CAR-T
gene editing
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
Tue, 02/20/18 - 09:58 am
CAR-T
ICER
Gilead Sciences
Yescarta
Novartis
Kymriah
drug pricing
How Celgene Hopes to Cash In on CAR-T
Yahoo/Motley Fool
Sat, 02/17/18 - 10:41 am
Celgene
CAR-T
JCAR017
bb2121
Bluebird Bio
As CAR-Ts go from candidates to brands, what's the marketing strategy?
Medical Marketing and Media
Tue, 02/13/18 - 09:01 am
CAR-T
drug marketing
JCAR017
Juno Therapeutics
Celgene
bb2121
Bluebird Bio
apalutamide
Janssen
Novartis move signals further gene therapy resurgence
EP Vantage
Fri, 01/26/18 - 11:12 am
Novartis
gene therapy
Spark Therapeutics
CAR-T
Luxturna
Bluebird Bio Shouldn’t Be Blue About Celgene’s Juno Deal
Washington Post, DC
Tue, 01/23/18 - 08:43 am
Bluebird Bio
Celgene
Juno Therapeutics
M&A
CAR-T
What to Expect From Amgen, Inc. in 2018
Motley Fool
Sun, 01/21/18 - 10:40 am
Amgen
Enbrel
Neulasta
Aranesp
Epogen
Neupogen
Prolia
Repatha
CAR-T
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Endpoints
Thu, 01/18/18 - 10:06 am
CAR-T
Gilead Sciences
Pfizer
utomilumab
Yescarta
large B-cell lymphoma
Celgene is reportedly in talks to buy Juno Therapeutics
CNBC
Wed, 01/17/18 - 11:40 am
Celgene
Juno Therapeutics
M&A
CAR-T
Vantage view – Payers OK with CAR-T? Not so fast
EP Vantage
Fri, 01/5/18 - 10:22 pm
CAR-T
payers
ICER
J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
Endpoints
Thu, 12/21/17 - 10:38 pm
JNJ
CAR-T
Legend Biotech
LCAR-B38M
BCMA
China
Juno inks CAR-T supply deal with Thermo Fisher
BioPharma Dive
Thu, 12/21/17 - 10:29 pm
Juno Therapeutics
Thermo Fisher
CAR-T
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Endpoints
Thu, 12/21/17 - 10:12 am
Kymriah
Yescarta
CAR-T
Novartis
Kite Pharma
Gilead Sciences
drug pricing
Celgene Shareholders Excited by CAR-T News
Motley Fool
Tue, 12/19/17 - 08:10 pm
Celgene
CAR-T
Bluebird Bio
bb2121
Is Gilead’s new CAR-T overpriced or is payer bureaucracy to blame for slow pickup?
Fierce Pharma
Fri, 12/15/17 - 11:35 pm
Gilead Sciences
CAR-T
drug pricing
Yescarta
ASH 2017: CAR-T Wallops Blood Cancer
Motley Fool
Tue, 12/12/17 - 11:16 am
ASH2017
CAR-T
gene therapy
Novartis
Kymriah
Yescarta
Gilead Sciences
Juno Therapeutics
JCAR017
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results
Motley Fool
Mon, 12/11/17 - 10:02 am
Bluebird Bio
bb2121
CAR-T
Celgene
Multiple Myeloma
ASH17
ASH17: Benefit of Gilead's CAR-T remains durable over longer term
BioPharma Dive
Sun, 12/10/17 - 11:27 pm
ASH17
Gilead Sciences
CAR-T
Yescarta
diffuse large B-cell lymphoma
Pages
« first
‹ previous
…
13
14
15
16
17
18
19
20
21
…
next ›
last »